FDA Rx Risk Advisor Seligman Joins From DoE, Reports To CDER's Galson
Executive Summary
Department of Energy Deputy Assistant Secretary for Health Studies Paul Seligman, MD, will handle pharmaceutical risk management initiatives at FDA in his new position as senior advisor.
You may also be interested in...
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.
FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011